ALXO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.362

-34.09%

-0.315

-45.69%

-0.300

-38.78%

Estimates Revision

Stock Price

Go Down

-36.08%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ALXO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALXO is 3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

3.00

High

4.00

Current: 0.000

Low

2.00

Averages

3.00

High

4.00

Jefferies

NULL -> Buy

initiated

2025-11-13

Reason

Jefferies

Price Target

2025-11-13

initiated

NULL -> Buy

Reason

Jefferies initiated coverage of ALX Oncology with a Buy rating and $4 price target. ALX has strategically focused on two lead programs, Evorpacept in post-ENHERTU HER2+ mBC using prospective CD47 enrichment, supported by "encouraging" gastric data and ALX2004, an ADC with a differentiated design for wider therapeutic window in solid tumors, the analyst tells investors.

UBS

Buy

downgrade

2025-05-21

Reason

UBS

Price Target

2025-05-21

downgrade

Buy

Reason

UBS lowered the firm's price target on ALX Oncology to $1 from $1.20 and keeps a Buy rating on the shares.

H.C. Wainwright

Buy

downgrade

$5 -> $2

2025-05-09

Reason

H.C. Wainwright

Price Target

$5 -> $2

2025-05-09

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on ALX Oncology to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA's feedback, the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-07

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-07

Reiterates

Strong Buy

Reason

Stifel

Bradley Canino

Hold

Maintains

$3 → $1.5

2025-03-07

Reason

Stifel

Bradley Canino

Price Target

$3 → $1.5

2025-03-07

Maintains

Hold

Reason

Stifel lowered the firm's price target on ALX Oncology to $1.50 from $3 and keeps a Hold rating on the shares. Following a R&D day and the company's Q4 report, the firm updated its model for the quarter, restructuring, and updated cash guidance, but has reduced its odds of success and confidence in gastric cancer and awaits proof of concept data in additional tumor type regimens.

Jefferies

Michael Yee

Hold

Strong Buy

Upgrades

$2 → $3

2025-03-06

Reason

Jefferies

Michael Yee

Price Target

$2 → $3

2025-03-06

Upgrades

Hold

Strong Buy

Reason

Jefferies analyst Michael Yee upgraded ALX Oncology to Buy from Hold with a price target of $3, up from $2. The company hosted a research and development day with two leading key opinion leaders in breast cancer and colorectal cancer to support the announcement of two new randomized Phase II studies starting up in each of these "big" solid tumor markets, the analyst tells investors in a research note. The firm says the two studies in breast cancer and colorectal would bring significant share upside with positive data in 2026, "which is really the long-term play here." The upgrade is based on the stock's risk/reward as it trades well below ALX's cash and has some catalysts, contends Jefferies.

Valuation Metrics

The current forward P/E ratio for ALX Oncology Holdings Inc (ALXO.O) is -0.92, compared to its 5-year average forward P/E of -7.70. For a more detailed relative valuation and DCF analysis to assess ALX Oncology Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.70

Current PE

-0.92

Overvalued PE

3.88

Undervalued PE

-19.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.37

Undervalued EV/EBITDA

-14.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

925.16

Current PS

0.00

Overvalued PS

4958.97

Undervalued PS

-3108.65

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALXO News & Events

Events Timeline

No data

News

1.0

01-08Globenewswire

ALX Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026

9.5

01-08NASDAQ.COM

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

9.0

2025-12-08NASDAQ.COM

ALXO Unveils Phase 2 Results of Evorpacept for Frontline Indolent Non-Hodgkin Lymphoma at ASH Conference

People Also Watch

Frequently Asked Questions

What is ALX Oncology Holdings Inc (ALXO) stock price today?

The current price of ALXO is 1.24 USD — it has increased 5.08 % in the last trading day.

What is ALX Oncology Holdings Inc (ALXO)'s business?

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

What is the price predicton of ALXO Stock?

What is ALX Oncology Holdings Inc (ALXO)'s revenue for the last quarter?

ALX Oncology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is ALX Oncology Holdings Inc (ALXO)'s earnings per share (EPS) for the last quarter?

ALX Oncology Holdings Inc. EPS for the last quarter amounts to -0.41 USD, decreased -29.31 % YoY.

What changes have occurred in the market's expectations for ALX Oncology Holdings Inc (ALXO)'s fundamentals?

The market is revising No Change the revenue expectations for ALXO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -36.08%.

How many employees does ALX Oncology Holdings Inc (ALXO). have?

ALX Oncology Holdings Inc (ALXO) has 80 emplpoyees as of January 09 2026.

What is ALX Oncology Holdings Inc (ALXO) market cap?

Today ALXO has the market capitalization of 67.23M USD.